RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $148
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Sarepta Therapeutics (NASDAQ:SRPT), but lowered the price target from $217 to $148.
October 31, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sarepta Therapeutics' price target has been lowered by RBC Capital from $217 to $148, though the 'Outperform' rating is maintained.
The lowering of the price target by RBC Capital indicates a potential decrease in the stock's value in the short term. However, the maintained 'Outperform' rating suggests that the stock is still expected to outperform the market or its sector, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100